B
SLRN

Braidwell’s ACELYRIN SLRN Stock Holding History

Braidwell’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500,000
Closed -$10.4M – 94
2023
Q2 		$10.4M Buy
+500,000
New +$10.2M 0.34% 69

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Braidwell's SLRN Position: Q3 2023 in Review

Braidwell sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 500,000 shares — an estimated $10.4M sold.

Braidwell first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $10.4M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

  • Braidwell reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
  • Braidwell sold 500,000 ACELYRIN shares in Q3 2023, an estimated $10.4M.
  • Braidwell first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
  • Braidwell's ACELYRIN position peaked at $10.4M in Q2 2023.
  • 101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.